AI assistant
Sending…
BridgeBio Pharma, Inc. — Director's Dealing 2020
Feb 15, 2020
30604_dirs_2020-02-14_adff0897-e6e1-4234-8187-bd632b8a6b99.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-02-12
Reporting Person: MOMTAZEE JAMES C (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-02-12 | Common Stock | A | 8491 | $0.00 | Acquired | 8491 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-02-12 | Stock Option (Right to Buy) | $34.65 | A | 24927 | Acquired | 2030-02-11 | Common Stock (24927) | Direct |
More from BridgeBio Pharma, Inc.
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 8
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 3